KitoMax®

Clinically Proven to:

  1. Reduce the post-prandial Cmax (maximum blood glucose levels) following meal by 13%
  2. Reduce the total blood glucose levels following mean by 8.5%
  3. Reduce HbA1c by 4%

 

KitoMax® is a patented, enzymatically-digested chitosan oligosaccharide that has demonstrated the positive effects of blood glucose levels and HbA1c levels in various clinical trials with healthy adults.  In two studies involving 22 volunteers, KitoMax® reduced the postprandial blood glucose levels after meal by as much as 13%. In another clinical trial with 51 healthy volunteers, KitoMax® administration for 12 weeks reduced HbA1C by 4%. HbA1c is a scientifically advanced test that measures the average blood glucose level over the previous 12 week period. It is a highly accurate way of evaluating long-term blood sugar maintenance and so is a preferred method used by doctors. Studies have shown that the health benefits of KitoMax® are due to the inhibition of carbohydrate digestion and uptake as well as the enhancement of adiponectin, a well-defined insulin sensitizer.

 

 

Summary of KitoMax® Clinical Trials:

 

  • Jo, S-H et al. (2014). Postprandial blood glucose level reducing effect of low molecular weight chitosan oligosaccharide, GO2KA1, in healthy individuals. Food Sci. Biotech. 23: 971-973

 

Subjects took one dose of either KitoMax® or placebo 20 minutes prior to consuming 75 mg of sucrose administered using an Oral Sucrose Tolerance Test. Compared to placebo, significant reductions in blood sugar (-13%; p ≤ 0.01) were observed after consumption of KitoMax® while the peak glucose level (Cmax) was also significantly lower (-9.9%; p ≤ 0.05) for KitoMax® subjects (Figure 1). The area-under-the-curve (AUC) over the two hour test period was 8.3% lower for KitoMax® (p ≤ 0.05 vs. placebo). 

 

  • Kang, Y-R, et al. (2016) Effect of supplementation of Low-Molecular-Weight Chitosan Oligosaccharide, GO2KA1, on postprandial blood glucose levels in healthy individuals following bread consumption. Food Sci. Biotechnol. 25:1-4

 

Subjects took one dose of either KitoMax® or placebo 20 minutes prior to consuming 3 slices of bread administered using an Oral Carbohydrate Tolerance Test. Compared to placebo, significant reductions in blood sugar (-12%; p ≤ 0.01) were observed after consumption of Orisett™ while the peak glucose level (Cmax) was also significantly lower (-11%; p ≤ 0.01) for KitoMAx® subjects . The area-under-the-curve (AUC) over the two hour test period was 6% lower for KitoMax® (p ≤ 0.05 vs. placebo).

 

  • Kim, H-J., et al. (2014). The effect of chitosan-oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes. Food & Funct., DOI: 10.1039/c4fo00469h

 

Fifty-one healthy subjects took one dose of either KitoMax® or placebo three times daily for 12 weeks. After a 12-hour washout period at the end of the study, post-prandial blood sugar was evaluated by giving subjects 75 g of glucose using an Oral Glucose Tolerance Test. Compared to Week 0 results, post-meal blood sugar levels in KitoMax® subjects at Week 12 were significantly reduced both 30 minutes (-9.1%) and at Tmax , 60 minutes (-8.7%) after ingestion of sucrose (p ≤ 0.05). In contrast, the glycemic response of the placebo group was no different between Week 0 and Week 12. AUC and Cmax were reduced for the KitoMax® group between Week 0 and Week 12 (AUC = -6%, p = 0.06; Cmax = -8.7%, p ≤ 0.05) but not for the placebo group. Additionally, consumption of KitoMax® resulted in a significant reduction (4%, p<0.05) in HbA1c compared to placebo after 12 weeks. HbA1c is a scientifically advanced test that measures the average blood glucose level over the previous 12 week period. It is a highly accurate way of evaluating long-term blood sugar maintenance and so is a preferred method used by doctors.

Take the first step towards healthy aging